BBIO Stock Price, Chart, Stats & News
BBIO chart
Fundamentals
Gross margin | 94.37% |
Operating margin | -113.35% |
Pretax margin | -146.39% |
Net margin | -145.26% |
Effective tax rate | -0.08% |
ROA | -77.92% |
ROE | 39.18% |
D/E | -1.31x |
Interest coverage ratio | -5.50x |
BBIO valuation
P/E | – |
P/S | 26.91x |
P/B | -6.62x |
P/CF | -30.83x |
P/FCF | -29.53x |
P/OCF | -30.83x |
PEG | -1.97x |
EV multiple | -18.24x |
About
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Similar securities
Based on sector and market capitalization
